R. Allerton
Russells Hall Hospital(GB)
Publications by Year
Research Areas
Ovarian cancer diagnosis and treatment, HER2/EGFR in Cancer Research, Endometrial and Cervical Cancer Treatments, Cancer Treatment and Pharmacology, Advanced Breast Cancer Therapies
Most-Cited Works
- → Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial(2018)604 cited
- → Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial(2019)438 cited
- → 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial(2019)278 cited
- → CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer(2015)249 cited
- → Lung Cancer After Hodgkin’s Disease: A Nested Case-Control Study of the Relation to Treatment(2001)132 cited
- → Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial(2018)80 cited
- → Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer(2021)45 cited
- → Cerebel (EGF111438): An Open Label Randomized Phase III Study Comparing the Incidence of CNS Metastases in Patients (PTS) with HER2+ Metastatic Breast Cancer (MBC), Treated with Lapatinib Plus Capecitabine (LC) Versus Trastuzumab Plus Capecitabine (TC)(2012)36 cited
- → Hormone Therapy for Breast Cancer in Men(2015)25 cited
- → Acute mesenteric ischaemia associated with 5-FU, cisplatin and vincristine chemotherapy(1996)23 cited